Advanced Hodgkin Lymphoma clinical trials

Explore recruiting advanced hodgkin lymphoma clinical trials.

Recruiting advanced hodgkin lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Hodgkin Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE)

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

EORTC-1537-LYMG: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study

Denmark, Portugal, Spain, Poland, Slovakia, Belgium +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Advanced Hodgkin Lymphoma trials by city

Advanced Hodgkin Lymphoma clinical trials

Recruiting advanced hodgkin lymphoma studies right now

A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors

Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors

Evaluation of Skin Tests in Biotherapy Allergies

A Study of NX-1607 in Adults With Advanced Malignancies

PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma

Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study

An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

Also recruiting in Europe

Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE)

EORTC-1537-LYMG: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study

Advanced Hodgkin Lymphoma trials by city

Other conditions